Sequenom (SQNM) Receives Notice That SEC is Investigating April 29 Announcement Regarding SEQureDx Down Syndrom Test
More News related to SQNM
- Sequenom (SQNM) volatility suggests movement
- Sequenom (SQNM) Announces that Dr. Yves Ville Joins Clinical Advisory Board
- Sequenom Announces New Clinical Advisory Board Member
- Sequenom (SQNM) Sees Upside Action
- Skymark Research Initiates Independent Research Coverage on Sequenom, Inc.
More News related to Corporate News
- Dahlman Rose Initiates Coverage on Independent Oil & Gas Stocks
- Sandler O'Neill Initiates Coverage on AON Corp. (AON) with a Hold
- Ameriprise Financial Initiates Coverage on Janus Capital (JNS) with a Buy
- BGB Securities Initiates Coverage on International Flavors & Fragrances (IFF) with a Buy
- Barrington Research Initiates Coverage on Masimo (MASI) with an Outperform
In a Form 8-K, Sequenom (Nasdaq: SQNM) disclosed that on June 29, 2009, it received written notification that the SEC has initiated an investigation relating to our April 29, 2009 announcement regarding it's SEQureDx Down syndrome test. Sequenom said it intends to cooperate fully with the SEC in this matter and that its internal investigation is ongoing.
Related Categories
Corporate NewsStocks Mentioned
+0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
